The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment outcome and recovery from peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer (JFMC41-1001-C2: JOIN Trial).
 
Dai Manaka
No Relationships to Disclose
 
Masahito Kotaka
Honoraria - Chugai Pharma; Merck Serono; Takeda; Yakult Pharmaceutical
 
Katsunori Shinozaki
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline/Novartis; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma
 
Tetsuo Touyama
No Relationships to Disclose
 
Takanori Matsui
No Relationships to Disclose
 
Kiyoshi Ishigure
No Relationships to Disclose
 
Junichi Hasegawa
No Relationships to Disclose
 
Keiji Inoue
No Relationships to Disclose
 
Yoshinori Munemoto
No Relationships to Disclose
 
Akinori Takagane
No Relationships to Disclose
 
Hiroshi Ishikawa
No Relationships to Disclose
 
Hideyuki Ishida
No Relationships to Disclose
 
Yutaka Ogata
No Relationships to Disclose
 
Koji Oba
Honoraria - Bayer; Chugai Pharma; Olympus; Taiho Pharmaceutical
 
Koichi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical
Research Funding - Amgen Astellas BioPharma; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; OxOnc; Pfizer; Riken Genesis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
 
Junichi Sakamoto
Honoraria - Yakult Pharmaceutical
Consulting or Advisory Role - Takeda
 
Shigetoyo Saji
No Relationships to Disclose
 
Atsushi Ohtsu
Employment - Celgene (I)
Research Funding - Bristol-Myers Squibb
 
Toshiaki Watanabe
Honoraria - Bayer; Chugai Pharma; Olympus; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Taiho Pharmaceutical
Speakers' Bureau - Abbvie; Ajinomoto; Amco; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Covidien; Eisai; Fujirebio Diagnostics; Intuitive Surgical; JIMRO; Johnson & Johnson; Kaken Pharmaceutical; Kyowa Hakko Kirin; MC Medical; Merck Serono; Mitsubishi Tanabe Pharma; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical; Zeria Pharmaceutical
Research Funding - Ajinomoto; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kaken Pharmaceutical; Kyorin; Kyowa Hakko Kirin; Merck Serono; Mitsubishi Tanabe Pharma; Miyarisan Pharmaceutical; Otsuka; Shionogi; Taiho Pharmaceutical; Taisho Toyama Pharma; Takeda; Toyama Chemical Co; Tsumura & Co.; Yakult Pharmaceutical
 
Takayuki Yoshino
Research Funding - Boehringer Ingelheim; GlaxoSmithKline